Vistin Pharma: third-quarter EBITDA falls, board approves NOK 0.50 dividend
Vistin Pharma's Q3 2026 EBITDA dropped to NOK 19M on revenue of NOK 108.4M. The board approved a cash dividend of NOK 0.50 per share.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Vistin Pharma ASA reported third-quarter 2026 revenue of NOK 108.4 million, compared with NOK 108.8 million a year earlier. EBITDA fell to NOK 19 million from NOK 28 million, and net profit dropped to NOK 11 million from NOK 18.5 million.
The board approved an additional cash dividend of NOK 0.50 per share, payable in November. Nine-month EBITDA came in at NOK 68 million versus NOK 88 million a year earlier. According to the company, it has no bank debt, holds NOK 22 million in cash, and reports an equity ratio of 78%.
The information was published by GlobeNewswire.
why it matters
The report shows steady volumes, including 13% growth, but profits are under pressure from currency effects. Restoring EBITDA would require a more favourable exchange rate, higher prices or better capacity utilisation, while the strong balance sheet supports the dividend.
tags
instruments
sources
- Vistin Pharma ASA (VISTN) Q3 EBITDA Falls; Adds NOK 0.50 Dividend — globenewswire.com, 29 October 2026 at 06:45 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗